Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy. Click here to find out why CAPR stock is a ...
Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of ...
Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort ...
Company preparing to resubmit CRL response under the current BLA Conference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR ...
Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 ...
A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy (DMD), a ...
NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...
Capricor Therapeutics has presented positive long-term data from its HOPE-2 clinical trial at the 2025 Muscular Dystrophy Association Conference, indicating that its leading treatment, deramiocel, can ...
STATEN ISLAND, N.Y. — Those who participated in “The 13th annual Michael 2025 Step For A Cure 5k Run And Walk” at the FDR ...
Every movement we make, whether walking, speaking or even breathing, depends on the health of our muscles and nerves.
The seventh annual Calves to Cure DMD charity cattle auction raised funds to help fund research for Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback